Ultragenyx Pharmaceutical (RARE) Capital Expenditures Growth (5y) (2018 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Ultragenyx Pharmaceutical | 2.29 Bn | 1.89 Bn | 106.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -42.86% |
| Dec 31, 2025 | -14.90% |
| Sep 30, 2025 | -19.50% |
| Jun 30, 2025 | -7.37% |
| Mar 31, 2025 | -41.09% |
| Dec 31, 2024 | -57.31% |
| Sep 30, 2024 | 3.36% |
| Jun 30, 2024 | -15.69% |
| Mar 31, 2024 | -15.99% |
| Dec 31, 2023 | -96.65% |
| Sep 30, 2023 | 104.16% |
| Jun 30, 2023 | -33.45% |
| Mar 31, 2023 | 80.64% |
| Dec 31, 2022 | -10.60% |
| Sep 30, 2022 | -35.10% |
| Jun 30, 2022 | -46.24% |
| Mar 31, 2022 | 119.62% |
| Dec 31, 2021 | 29.99% |
| Sep 30, 2021 | 46.94% |
| Jun 30, 2021 | 31.81% |
| Mar 31, 2021 | 61.87% |
| Dec 31, 2020 | 62.73% |
| Sep 30, 2020 | 13.83% |
| Jun 30, 2020 | 46.99% |
| Mar 31, 2020 | 98.36% |
| Dec 31, 2019 | 58.22% |
| Sep 30, 2019 | 27.34% |
| Jun 30, 2019 | 73.97% |
| Mar 31, 2019 | 39.99% |
| Dec 31, 2018 | 56.00% |
| Sep 30, 2018 | 38.43% |
| Jun 30, 2018 | 73.01% |
| Mar 31, 2018 | 21.83% |